Metacognitive Therapy for Health Anxiety

Hypochondriasis Clinical Trial

Official title:

Metacognitive Therapy for Health Anxiety: A Randomised Control Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02404116
• Other study ID #: : z83hdhmg
• Status: Completed
• Phase: N/A
• First received: March 23, 2015
• Last updated: February 6, 2017
• Start date: March 2015
• Est. completion date: January 2017

Study information

• Verified date: February 2017
• Source: University of Manchester
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study involves a comparing a new psychological treatment- Metacognitive Therapy (MCT) which has shown promising results in the treatment of health anxiety to no treatment at all- a waiting list.

Description:

Hypochondriasis or severe health anxiety is characterised by excessive, disproportionate and persistent thoughts, behaviour and emotion focused on physical symptoms and/or fear of developing a serious illness. There is often excessive worry about illness or disease in the absence of supporting medical evidence and contrary to continual medical reassurance.

The most effective psychological treatments are cognitive and behavioural therapies (CBT). However, CBT has failed to demonstrate consistent gains in the treatment of this disorder.

A newer form of psychological therapy, Metacognitive Therapy (MCT) has shown to be more effective than CBT in the treatment of anxiety disorders and depression. MCT is based on the principle that health anxiety is caused by a pattern of extended thinking, this pattern is called the Cognitive Attentional Syndrome (CAS). The CAS is made up of chains of verbal thought in the form of excessive worry about having an illness; a pattern of focusing attention on threat, such as scanning the body for signs of illness and excessive body checking; and coping strategies that have negative effects, such as internet searching for illnesses or trying to block out thoughts of illness. Rather than stopping negative thinking the CAS extends it and leads to the belief that illness is present. To help reduce these symptoms MCT teaches specific techniques that help people develop new ways of experiencing negative thoughts about illnesses, allow them to abandon worry and learn to disengage from unhelpful coping attempts.

A recent small study has provided some limited evidence that metacognitive therapy (MCT) can be applied to cases of hypochondriasis and demonstrated that the therapy was associated with improvement in symptoms.

To provide future evaluation of MCT in this client group a more definitive trial will be carried out to ascertain the effects of MCT in a larger group when compared to a control group.

If the results are positive this will provide a rationale for a larger research study, which will compare MCT with evidence based treatment such as CBT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Be over 18.

• Exceed cut off on BP and WI

• Not undergoing any other form of psychological therapy during treatment.

• If on medication must be stable six weeks prior to treatment onset.

• Willing to undergo randomisation

• Provide written consent

Exclusion Criteria:

• Be under 18

• Not exceeding cut off on BP and WI

• Undergone CBT for health anxiety over the past three months.

• Having started medication less than four weeks before assessment

• Not willing to undergo randomisation

• Not willing to provide written consent

Related Conditions & MeSH terms

• Hypochondriasis

Intervention

Other:
• Metacognitive Therapy
Participants will receive treatment which focus's on helping reduce excessive thinking about health,
• Wait List
Individuals are on a waiting list

Locations

Country	Name	City	State
United Kingdom	University of Manchester	Manchester
United Kingdom	University of Central Lancashire	Preston	Lancashire

Sponsors (1)

Lead Sponsor	Collaborator
University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in health anxiety levels over 12weeks of treatment measured by the Whiteley Index 7 (WI7)	Measures the presence of health anxiety.	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion
Primary	Change in health anxiety levels over 12weeks of treatment measured by the Bodily Perception Questionnaire (BP).	Measures the presence of health anxiety.	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion
Secondary	Change in anxiety levels over 12weeks of treatment measured by the Beck Anxiety Inventory	Will be used as a measure of anxiety	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion
Secondary	Change in general metacognition levels over 12weeks of treatment measured by the The Metacognitions Questionaire-30 (MCQ-30)	will be used to examine general positive and negative beliefs about worrying thoughts, attitudes & processes.	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion
Secondary	Change in depression levels over 12weeks of treatment measured by the Beck Depression inventory	Will be used as general mood measures	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion
Secondary	Change in health anxious metacognition levels over 12weeks of treatment measured by the The Meta-Cognitions about Health Questionnaire (MCHQ)	Specific metacognitive beliefs associated with health anxiety	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion
Secondary	Change in dysfunctional beliefs over 12weeks of treatment measured by the Health cognition Questionnaire	Dysfunctional beliefs associated with health anxiety	This will be administered in the first and last treatment session (week 1 and week 12) by the study investigators, and once at 6 months follow up following treatment completion